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The inflammatory component of multiple sclerosis (MS) 
pathology can be focal or diffuse and is associated with 
neurodegenerative processes that ultimately lead to 
irreversible tissue damage and neuronal loss1. Neuro­
degeneration was originally thought to be a late­ stage 
phenomenon with limited clinical relevance, but it is 
now recognized as being associated with acute inflam­
mation from the early stages of MS and as the main driver 
of irreversible disability2–5. In parallel with improvements 
in our understanding of the mechanisms of neurodegen­
eration, advances in imaging techniques have enabled 
in vivo assessment of brain and spinal cord area and vol­
umes using MRI. Although brain and spinal cord volume 
loss observed with MRI cannot be equated with atrophy6, 
because the latter implies pathologically proven and irre­
versible tissue loss, changes in these MRI measures are 
associated with atrophy7 and the level of disability in MS8,9.
MRI­ based quantification of inflammatory activity in 
MS — on the basis of lesion counts and lesion volumes 
— is established as the main efficacy outcome in phase II 
clinical trials10. Currently, brain and spinal cord volume 
measures have no role in the MS diagnostic criteria11,12 
or disease course classification13, but a body of evidence 
that these measures are valuable for early evaluation of 
treatment responses and prediction of disease evolution 
has been steadily growing alongside improvements in 
methodology that could facilitate widespread implemen­
tation of these measures in clinical practice14,15. A key 
difficulty arises in this implementation because transla­
tion of group­ based results into actionable, patient­ level 
information must be made with extreme caution.
In this Consensus Statement, we, on behalf of the 
Magnetic Resonance in Imaging in MS (MAGNIMS) 
study group, provide specific recommendations for the 
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Abstract | Early evaluation of treatment response and prediction of disease evolution are key 
issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has 
become the most useful paraclinical tool in both situations and is used clinically to assess the 
inflammatory component of the disease, particularly the presence and evolution of focal lesions 
— the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at 
least partly independent of inflammatory mechanisms can develop early in people with MS and 
are closely related to disability. The effects of these neurodegenerative processes at a macroscopic 
level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements 
of atrophy in MS have also been proposed as a complementary approach to lesion assessment to 
facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus 
statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review  
the application of brain and spinal cord atrophy in clinical practice in the management of MS, 
considering the role of atrophy measures in prognosis and treatment monitoring and the barriers 
to clinical use of these measures. On the basis of this review, the group makes consensus statements 
and recommendations for future research.
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implementation of brain and spinal cord atrophy meas­
ures in the clinical management of patients with MS 
and on the directions of future research to improve our 
knowledge in this field. The recommendations are based 
on a critical review of the literature and the personal 
experience of MAGNIMS study group members. We dis­
cuss the difficulties of translating group­ based data into 
clinical application and highlight where particular cau­
tion is appropriate. We first discuss the role of atrophy 
measures on prognosis, then treatment monitoring and, 
finally, the barriers to implementation in clinical prac­
tice. Each of these three sections comprises a review of 
the available evidence and a set of consensus guidelines.
Methods
A multicentre international panel on the implementa­
tion of brain and spinal cord atrophy measures in clinical 
practice convened in Barcelona, Spain, under the aus­
pices of MAGNIMS, an independent European network 
of clinical research groups with a common interest in 
the study of MS with MRI. The panel was made up of 
experts in the diagnosis and management of MS, includ­
ing neuroradiologists, neurologists, physicists, imaging 
methodologists and statisticians, who were selected by 
the workshop organizers (with approval from all mem­
bers of the Steering Committee) on the basis of their 
personal expertise, from MAGNIMS centres from seven 
different countries. The purpose of this face­ to­face 
meeting was to review and discuss all published data 
on brain and spinal cord atrophy in MS and to consider 
whether the previously published recommendations16,17 
on its use for diagnosis, prognosis and monitoring of 
patients with MS needed to be revised and updated in 
view of technical advances and numerous clinical studies 
of atrophy in MS. The panel agreed that updated recom­
mendations were necessary. After this meeting, the panel 
members formulated specific recommendations in 
relation to the implementation of brain and spinal cord 
atrophy measures in clinical practice.
The authors of the Consensus statement are mem­
bers of the MAGNIMS Study Group. The network 
is independent of any other organization and, at the 
time of the workshop mentioned above, was run by a 
Steering Committee whose members were À. Rovira 
(Barcelona, co­ chair), C. Enzinger (Graz, co­chair), 
F. Barkhof (Amsterdam), O. Ciccarelli (London), 
N. de Stefano (Siena), M. Filippi (Milan), J. Frederiksen 
(Copenhagen), C. Gasperini (Rome), L. Kappos (Basel), 
J. Palace (Oxford), M.A. Rocca (Milan), J. Sastre­ Garriga 
(Barcelona), H. Vrenken (Amsterdam) and T. Yousry 
(London). The first draft of the recommendations was 
written by the principal authors (J.S.­G., D.P. and M.B.) on 
the basis of the panellists’ presentations and contributions 
to discussions on specific topics, which were assigned to 
individuals according to each member’s area of expertise. 
The initial draft was then circulated among all authors 
(who were all presenters and/or discussants at the meet­
ing). Modifications were made iteratively until consensus 
was reached on all recommendations; all panel members 
agreed on the full contents of the final recommendations.
Defining and predicting MS severity
Evidence review
Global brain volume measures to define and predict 
MS severity. The initial studies to investigate clinical 
correlates of brain atrophy in MS focused on patients 
with well­ established disease and severe clinical mani­
festations, particularly in the cognitive sphere18–20, but 
later studies included disability, as measured with the 
Expanded Disability Status Scale8. Evidence from these 
studies made it clear that neurodegenerative proces­
ses occur in the earliest phases of MS21, even before the 
disease becomes symptomatic22.
Yearly global brain volume loss in healthy ageing 
individuals ranges from –0.05% at 20–30 years of age 
to –0.3% at 60–70 years of age23. A change of –0.4% per 
year has been proposed as the cut­ off for pathological 
brain atrophy in MS24 (Fig. 1), although care must be 
taken before applying this threshold as a marker of ther­
apeutic efficacy owing to the phenomenon of pseudo­
atrophy (see Brain volume as an outcome measure in 
randomized clinical trials)25,26. Multiple studies have 
shown that short­ term changes (over as little as 1 year) in 
brain volume are predictive of clinical status (diagnosis 
of MS or disability status) at various follow­ up times in 
clinically isolated syndromes27,28, relapsing–remitting 
MS (RRMS)29 and primary progressive MS30–32, either in 
isolation or together with lesion­ related parameters33,34.
The findings above are group­ based results, and 
translation of these findings to the individual level is not 
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T2LL = 1,030 mm3 T2LL = 730 mm3 T2LL = 673 mm3 T2LL = 661 mm3 T2LL = 2,423 mm3
BPF = 82% BPF = 80.9% BPF = 79.8% BPF = 79.7% BPF = 77.2%
Fig. 1 | Lesion load and brain atrophy in relapsing–remitting multiple sclerosis. a | Transverse T2-weighted fluid 
attenuation inversion recovery images from a patient with highly active relapsing–remitting multiple sclerosis (MS)  
who started a disease- modifying therapy at baseline. The T2 lesion load (T2LL) is stable during the first 3 years of treatment 
while the patient remained clinically stable (no relapses and no disability worsening), but markedly increases at the  
fourth year after treatment discontinuation associated with clinical activity (the rebound effect). b | Contrast- enhanced 
T1-weighted images from the same patient showing the change in brain parenchymal fraction (BPF) over time. The 
decrease in global brain volume in the first 3 years is mild (annualized percentage of brain volume change (aPBVC) 
−0.089%), but the volume loss at the fourth year is severe (aPBVC −3.8%), matching the change in T2LL and clinical 
evolution. The severe loss observed in year 4 is well beyond the −0.4% suggested as a pathological cut- off for brain volume 
loss in MS24. c | Graphical representation of the changes in BPF over time, emphasizing the dramatic loss of volume in year 4.
straightforward. In a study published in 2017, Sormani 
et al.35 made the first attempt to define individual cut­ off 
values for brain volume changes according to patients’ 
baseline characteristics. Pooled baseline data from the 
placebo arms of two large international clinical trials that 
involved a total of 2,342 patients with RRMS showed 
that expected normalized brain volumes can be calcu­
lated from demographic (age and sex), clinical (Expan­
ded Disability Status Scale score and disease duration) 
and neuroradiological (T2­weighted lesion volume) 
parameters for individuals. Deviation of the true brain 
volume from this expected value enabled classification 
of individuals with MS as having low, medium or high 
brain volume. Patients with low brain volume had a 
2.4­fold higher risk of disability progression over the 
next 2 years than patients with high brain volume.
Spinal cord atrophy measures to define and predict MS 
severity. Early, seminal studies of cervical cord atrophy 
in MS already suggested that cervical spinal cord area is 
an important marker of disability status in MS9. Further 
studies demonstrated that spinal cord area and volume 
are affected differently in different MS subtypes, with the 
most profound atrophy in cross­ sectional studies being 
seen in patients with progressive MS36–39. Since 2015, 
an association between reduced cervical cord area and 
increased disability and motor dysfunction, indepen­
dent of brain atrophy, has been confirmed40–43. An asso­
ciation between cord atrophy and reduced peripapillary 
retinal nerve fibre layer thickness has been identified, 
indicating that cervical cord atrophy reflects, at least in 
part, global pathological processes and not only specific 
damage of long tracts41. Most studies of spinal cord area 
have focused on global cervical cord area measurements, 
but some work has highlighted that damage in particular 
locations in the spinal cord, such as cervical grey mat­
ter44, the thoracolumbar segment45 and the posterior and 
lateral cord segments46, are also relevant to disability.
Longitudinal studies indicate that atrophy rates in the 
spinal cord are higher than those in the brain and higher 
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in progressive MS than in established RRMS47,48. Higher 
rates of cervical cord area loss have been associated with 
disability progression, independent of other clinical 
and MRI parameters30,47 including spinal cord lesions49. 
However, as for brain atrophy, use of such group­ level 
evidence to inform clinical decisions at the individual 
level is not easy. Results that can be used at the individ­
ual level are slowly emerging; for example, Tsagkas et al.43  
have shown that a 1% increase in the annual rate of 
spinal cord atrophy increases the risk of disability pro­
gression by 28%, reinforcing the notion that spinal cord 
atrophy is a reliable and independent tool for monitoring 
disease progression.
Regional and tissue- specific brain volumetry measures 
to define and predict MS severity. Early cross­ sectional 
studies of brain white matter and grey matter changes 
in patients with MS indicated that both white mat­
ter and grey matter loss occurred early in the disease 
course, regardless of disease phenotype50–53. Evidence 
also indicates that grey matter damage can occur before 
white matter atrophy and can occur independently 
of white matter lesions54–56. Results of further longitudinal 
studies have identified larger decreases in grey matter 
volumes than in white matter volumes57–59 and that grey 
matter damage is more relevant than white matter injury 
to clinical outcomes, both concurrent and forthcom­
ing56,60–62. Two studies — one in which cortical thickness 
was estimated63 and one meta­ analysis of voxel­ based 
morphometry studies64 — have revealed statistically 
significant associations between disability end points 
and grey matter atrophy65, which occurs bilaterally, pre­
dominantly in the cingulate, pre­ central and/or post­ 
central gyri and the thalami and basal ganglia. Despite 
these results, global brain volume changes seem to be 
more strongly associated with clinical outcomes than 
are regional changes. This observation is unexpected 
because grey matter loss is thought to underlie disability 
accumulation. Associations between grey matter volume 
change and disability accumulation might be masked 
by the effects of high variability of regional segmenta­
tions, which makes clinical application of these regional 
measures inadvisable at present62,66.
Statements and recommendations
1. We recommend measurement of global brain volume 
to better gauge global disease burden in patients with 
MS because brain volume loss is associated with and 
predicts disability in all clinical MS phenotypes, 
including the earliest stages of the condition.
2. We recommend measurement of cervical cord area 
loss because this measure is associated with and pre­
dicts disability in all clinical MS phenotypes, including 
the earliest stages of the condition.
3. Grey matter volume changes in the brain are more 
pronounced and clinically relevant than white matter 
volume changes, even in the earliest stages of MS, but 
their exact relevance in clinical practice is unclear. We 
recommend further research to clarify this relevance.
4. Some cerebral grey matter regions (including the 
thalami, basal ganglia and specific cortical areas) are 
affected particularly strongly by atrophy in MS, but 
whether the pathological involvement of these areas 
is relevant in clinical practice remains unclear. We 
recommend further research to determine the clinical 
relevance of atrophy in these regions.
Monitoring therapeutic effect
Evidence review
Brain volume as an outcome measure in randomized 
clinical trials. Many trials of disease­ modifying thera­
pies for MS have included brain atrophy as an outcome 
measure (Table 1). Most early studies of interferon­β 
(IFNβ) and glatiramer acetate did not include preplanned 
brain volume measures as secondary MRI outcomes. 
Those that did include a sound comparison of brain 
volume changes between intervention arms or between 
intervention and placebo arms produced mixed results67.
The only study of IFNβ that provided evidence for 
a positive effect of treatment of brain atrophy was the 
ETOMS trial68. In this study, accrual of atrophy was 
reduced by 30% in patients with clinically isolated syn­
dromes who received low­ dose subcutaneous IFNβ1a 
compared with patients who received placebo68. In 
several trials — particularly the trial of intramuscular 
IFNβ1a in RRMS69,70 — negative results were at least 
partly attributed to a pseudoatrophy effect, caused by 
brain volume loss linked to the presumed treatment­ 
associated resolution of inflammatory activity and 
oedema. In the RRMS intramuscular IFNβ1a trial, 
significant differences that favoured treatment with 
IFNβ1a were only observed in the second year69,70. A post­ 
hoc analysis of grey matter and white matter atrophy 
during the 2 years of the trial confirmed this find­
ing and indicated that pseudoatrophy of white matter 
contributed most to the observed effect71. The same 
effect has been described in observational studies 
of patients taking natalizumab72 or IFNβ73, although 
more research is needed to confirm these findings. 
Results with glatiramer acetate were also mixed, though 
some nonprimary analyses have suggested a positive 
effect of the treatment in patients who received glatir­
amer acetate from the beginning of the trial when 
compared with those who received the treatment later74. 
Trials of IFNβ and of glatiramer acetate in progres­
sive MS have been negative75 or have also suggested a 
pseudoatrophy effect76.
Trials of natalizumab provided a clear demonstration 
of pseudoatrophy. In the AFFIRM trial77, brain volume 
decreases among patients who received natalizumab 
were larger in the first year than among patients who 
received placebo, but the observation was reversed in 
the second year. Subsequent clinical trials of newer 
drugs (including fingolimod, dimethyl fumarate, ter­
iflunomide, ocrelizumab and alemtuzumab) have all 
incorporated brain volume measures as secondary or 
tertiary outcomes, and results have been positive over­
all78, although studies are not readily comparable. Of 
note, in studies of powerful anti­ inflammatory drugs 
against active comparators, the trial drugs have been 
superior at decreasing accrual of atrophy79–81, indicating 
that the pseudoatrophy effect can be overcome by the 
beneficial effects of anti­ inflammatory drugs on neuro­
degeneration in MS. Strategies to minimize the effect of 
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pseudoatrophy on clinical measures include, but are not 
restricted to, obtaining baseline measurements once the 
anti­ inflammatory effect is well established (for example, 
re­ baseline with MRI at 6 or 12 months after treatment 
initiation)82,83.
Further support for the clinical relevance of brain vol­
ume outcomes in trials of treatment for RRMS comes 
from a meta­ analysis that included >13,500 patients from 
13 different clinical trials84. The conclusion of the analy­
sis was that the effect of a given therapy on changes in 
brain volume over 2 years is associated with the effect of 
the drug on disability outcomes and that this association 
is, at least in part, independent of its anti­inflammatory 
effect on active MRI lesions84. This close association 
between brain atrophy and disability outcomes in clinical 
trials has driven the adoption of brain volume change 
as a primary outcome in phase II trials in cohorts of 
patients with progressive MS85,86.
Spinal cord atrophy as an outcome in randomized 
clinical trials. Despite the relevance of spinal cord atro­
phy to long­term disability, this measure has scarcely 
been used as an outcome in clinical trials87; when it has been 
used, the results have been negative. For example, spinal 
cord atrophy was an outcome measure in an investigator­ 
initiated study of lamotrigine for neuroprotection in 
secondary progressive MS, but no differences were seen 
between the treatment and placebo arms88. Spinal cord 
atrophy measures have been used in several other studies 
in progressive MS89 but the atrophy and clinical results 
Table 1 | Brain atrophy outcomes in pivotal trials of approved disease- modifying drugs
Drug Clinical trial Phenotype Comparator Time frame Software Treatment 
favoured
IFNβ1a (SC) ETOMS68 CIS Placebo 0–24 months SIENA113 IFNβ1a (SC)
REFLEX155 CIS Placebo 0–24 months SIENA113 None
PRISMS156 RRMS Placeboa 0–6 years Kappos et al.156 None
IFNβ1b (SC) BENEFIT157 CIS Placeboa 0–36 months SIENA113 None
EUSPMS158 SPMS Placebo 0–36 months Losseff et al.8 None
Montalban et al.76 PPMS Placebo 0–24 months SPM51 None
IFNβ1a (IM) Rudick et al.69 RRMS Placebo 0–24 months Rudick et al.70 None
Leary et al.90 PPMS Placebo 0–24 months Fox et al.140 None
Glatiramer acetate PRECISE159 CIS Placebo 0–36 months SIENA113 None
Sormani et al.160 RRMS Placeboa 0–18 months SIENA113 Glatiramer 
acetate
PROMISE75 PPMS Placebo 0–36 months Wolinsky et al.75 None
Teriflunomide TOPIC161 CIS Placebo 0–24 months Miller et al.161 None
TEMSO162 RRMS Placebo 0–24 months Wolinsky et al.163 None
TEMSO164,b RRMS Placebo 0–24 months SIENA113 Teriflunomide
Dimethyl fumarate DEFINE82 RRMS Placebo 6–24 months SIENA113 Dimethyl 
fumarate
CONFIRM165 RRMS Placebo 0–24 months SIENA113 None
Natalizumab AFFIRM77 RRMS Placebo 0–24 months Rudick et al.70 Noned
SENTINEL166 RRMS Placeboc 0–24 months Rudick et al.70 Noned
ASCEND167 SPMS Placebo 24–96 weeks SIENAX113 None
Fingolimod FREEDOMS 1 (reF.168) RRMS Placebo 0–24 months SIENA113 Fingolimod
FREEDOMS 2 (reF.169) RRMS Placebo 0–24 months SIENA113 Fingolimod
TRANSFORMS81 RRMS IFNβ1a (IM) 0–12 months SIENA113 Fingolimod
INFORMS91 PPMS Placebo 0–36/60 months SIENA113 None
Alemtuzumab CARE- MS 1 (reF.79) RRMS IFNβ1a (SC) 0–24 months Rudick et al.70 Alemtuzumab
CARE- MS 2 (reF.80) RRMS IFNβ1a (SC) 0–24 months Rudick et al.70 Alemtuzumab
Ocrelizumab OPERA 1 (reF.170) RRMS IFNβ1a (SC) 24–96 weeks SIENA113 Ocrelizumab
OPERA 2 (reF.170) RRMS IFNβ1a (SC) 24–96 weeks SIENA113 Ocrelizumab
ORATORIO171 PPMS Placebo 24–120 weeks SIENA113 Ocrelizumab
Cladribine ORACLE172 CIS Placebo 0–24 months SIENA113 None
CL ARITY83 RRMS Placebo 6–24 months SIENA113 Cladribine
CIS, clinically isolated syndrome; IFN, interferon; IM, intramuscular ; PPMS, primary progressive multiple sclerosis; RRMS, relapsing–remitting multiple sclerosis; SC, 
subcutaneous; SIENA , Structural Image Evaluation, using Normalization, of Atrophy ; SPMS, secondary progressive multiple sclerosis. aIncludes a period receiving 
the active drug. bReanalysis of TEMSO trial data using SIENA. cAs an add- on to IFNβ1a (IM). dResults favoured natalizumab in the 12–24-month period.
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have either been negative76,90 or were not published with 
the rest of the trial91.
Brain volume and spinal cord atrophy to monitor 
clinical treatment response. The relevance of brain 
volume measures to the evolution of disability in MS 
clinical trials is beyond any doubt84. The evidence 
from trials is complemented by that from studies of 
individual­ level data from clinical trials92,93 and from 
observational studies of real­ world cohorts25,94, which 
confirm a close association between brain volume 
changes with therapy and concurrent95 or subsequent96 
disability progression. These studies also indicate that 
the association between brain volume loss and dis­
ability progression is independent of clinical and MRI 
inflammatory markers.
Most models for the prediction of disability progres­
sion have included brain volume change combined with 
either the appearance of new T2 lesions or the presence 
of clinical relapses25,92–94. Brain volume changes have 
also been proposed as an addition to the ‘no evidence of 
disease activity’97,98 outcome measure so as to enable 
assessment of neurodegenerative processes as well as 
inflammatory processes, with the aim of achieving full 
remission that includes an absence of disease­ specific 
neurodegeneration; the proposed cut­ off for this mea­
sure is –0.4% change in volume per year24. In a poten­
tially more realistic ‘minimal evidence of disease activity’ 
approach99, a less stringent cut­ off has been suggested 
that would allow for pseudoatrophy­ driven brain vol­
ume loss25. However, all these data need confirmation, 
and different cut­ offs might be needed for different 
calculation methods and for different drugs or groups of 
drugs according to different temporal patterns of brain 
volume effects of each drug6,78.
Statements and recommendations
1. We recommend the use of whole brain atrophy over 
a minimum period of 12 months as a secondary 
end point in clinical trials in MS and even as a pri­
mary outcome measure in trials in the progressive 
forms of MS to show the effects of the drug on the 
neurodegenerative component of the disease.
2. Ongoing and forthcoming trials are expected to 
include grey matter volume loss as an outcome mea­
sure, as atrophy in the grey matter compartment is 
more substantial and more clinically relevant than 
atrophy in the white matter and is likely to be affected 
less by pseudoatrophy; however, data on pseudoatro­
phy remain discordant and we recommend further 
research to clarify the contribution of grey matter 
atrophy.
3. Pseudoatrophy effects mostly occur within the first 
6–12 months from treatment initiation with any anti­ 
inflammatory therapy, so we recommend re­ baseline 
MRI at 6–12 months after initiation of any therapy 
to mitigate the impact of pseudoatrophy on outcome 
measures.
4. Associations between treatment effects on brain 
volume and disability have been demonstrated in 
clinical trials and indicated by evidence at the indi­
vidual level, but we recommend further research to 
confirm these associations before brain volume can be 
considered for use as a treatment­ monitoring tool.
5. Use of spinal cord atrophy as a treatment­ monitoring 
tool in clinical trials and in clinical practice has been 
scarce, but the rate of spinal cord atrophy is faster than 
that of brain atrophy and methodological advances 
could improve reproducibility and reliability, so we 
recommend further research to establish the role of 
spinal cord atrophy for treatment monitoring.
Barriers to clinical implementation
Evidence review: technical barriers
Several technical aspects of image acquisition and quan­
tification can affect the measurement of brain and spinal 
cord volumes and thereby affect the accuracy of estimated 
values. These technical barriers are discussed below.
Acquisition protocols. The choice of the acquisition 
parameters (usually repetition time, echo time, inversion 
time or flip angle) is usually based on the image con­
trast, as assessed visually by an expert neuroradiologist. 
Changes in scan parameters, which tend to happen in a 
clinical environment, affect quantification and hamper 
reliable cross­ sectional and longitudinal comparisons. 
Image contrast also depends greatly on the age of the 
population that undergoes MRI. The Alzheimer’s Disease 
Neuroimaging Initiative100 has made a large effort to 
homogenize acquisition protocols across vendors.
Gradient distortion. By design, the gradients applied 
to the magnetic field in MRI are generally not uni­
form, which affects the geometry of the image. Small 
displacements of the patient’s head in the z axis have a 
notable effect on the estimated brain volume change101. 
Positioning of the patient identically across scanning 
sessions can minimize this effect, but this is time­ 
consuming and difficult; a better solution is to apply 
approaches developed by MRI scanner manufacturers 
for 3D correction for the gradient nonlinearity effect102.
Intrascanner variability. Any MRI­ derived measure is 
inherently variable, even when technical and physio­
logical conditions are controlled103–108. Global estimates, 
such as that of the whole brain volume, are the least 
variable (<1%)106, whereas measures of smaller struc­
tures, such as the amygdala, are much more variable 
(~5%)104,105. Such variability must be taken into account 
because changes that are smaller than the estimated 
variability cannot be reliably detected. This limitation 
is highly relevant to small grey matter structures and 
when follow­ up periods are short because the expected 
change is small23.
Movement. Movement of the patient during image 
acquisition generates characteristic artefacts that affect 
image quality; as a result, estimated volumes are substan­
tially decreased109. Visual verification of image quality 
is important because the problem is resolved when the 
only images included in an analysis are those that an 
expert considers artefact free109. Various approaches have 
been developed to correct for movement, but an accurate 
method is still not available110.
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Scanner system upgrades and interscanner variability. 
Scanner upgrades are unavoidable, particularly during 
the course of longitudinal studies, and can affect the 
image contrast even if the same acquisition parameters 
are used. Previous studies have shown that the system 
upgrade should be included as a variable in the statis­
tical analysis103,111,112. Quantification methods based on 
the subtraction of images, rather than on differences in 
brain parenchymal fraction between two time points, seem 
to be more sensitive to system upgrades113, although no 
studies have been performed to confirm this observation. 
Reliable quantification of longitudinal changes in MS 
requires scans to be acquired with the same magnet and 
exactly the same sequence protocol. Variability between 
different scanners is higher than all the factors above 
together108. If data acquired in different scanners need 
to be merged, a variable that accounts for the scanner 
should be taken into consideration.
Evidence review: confounding factors
Numerous factors can have confounding effects on the 
quantification of brain volume (and its changes) and 
thereby cause overestimation or underestimation114. 
These factors are discussed below.
Age, sex and brain size. Several physiological factors 
influence brain volume estimations in healthy indi­
viduals. Studies of healthy elderly individuals have 
demonstrated ongoing brain volume loss, which tends 
to accelerate with age115. This age­ related effect is par­
ticularly pronounced for specific CNS structures, such 
as the hippocampus116.
Sex is another key factor in brain volume changes. 
Sex differences in global brain size in humans are well 
established; on average, the total volume of men’s brains 
is ~10% larger than that of women’s brains117. Differential 
patterns of age­ related brain volume loss118 and sex­ 
specific differences in brain morphology have also been 
demonstrated119,120. Global and regional volumetric stud­
ies have suggested that hormonal status can contribute 
to these sex­ related differences121.
Diurnal fluctuations and hydration state. Studies of 
healthy individuals have shown that estimations of brain 
volume fluctuate with the time of scanning and the 
hydra tion state of the individuals. Analysis of MRI data 
from patients with MS (n = 755, 3,269 scans) and from 
participants in the Alzheimer’s Disease Neuroimaging 
Initiative (n = 834, 6,114 scans) revealed that time of day 
had a notable effect on estimates of the brain parenchy­
mal fraction in both groups. Brain volumes were sub­
stantially larger in the morning122, and the effect size 
was comparable to the yearly rate of brain atrophy in 
MS and in healthy elderly people122. Similarly, in studies 
in which hydration status was manipulated by overnight 
thirsting and subsequent drinking of water, hydration­ 
related changes in brain volume were as large as –0.55% 
on dehydration and +0.72% on rehydration123.
Lifestyle and risk factors. Many lifestyle factors, includ­
ing physical activity124, influence estimates of brain vol­
ume. A higher level of alcohol intake has been associated 
with a higher rate of brain atrophy over a 6­year period115 
and with a specific pattern of regional involvement of the 
white matter and grey matter125. A similar effect has been 
described for cigarette smoking and substance abuse (for 
example, marijuana use)115,126. Many systemic conditions, 
such as diabetes, chronic kidney disease, hypertension, 
obesity and vascular conditions can also accelerate brain 
atrophy115,127,128.
The MS brain. All confounding factors previously 
discussed can interact with features of MS and affect 
estimates of brain atrophy in patients with the disease; 
these interactions can also affect comparisons between 
groups. For instance, more severe brain atrophy has been 
observed in patients with MS who have one or more 
cardio vascular risk factors129, although their impact on 
longitudinal assessments might be limited, as vascu­
lar risk factors were not associated with greater brain 
volume loss during 3.5 years of follow­ up in the same 
study129. In addition, white matter lesions in MS influ­
ence the accuracy of most available software for estima­
tion of atrophy because they alter the image intensity 
histogram and influence the detection of intensity bor­
ders between grey matter, white matter and cerebrospi­
nal fluid (CSF). This effect can be minimized by use of 
lesion filling techniques130,131, which enable replacement 
of lesions in the image with voxels that have intensities 
that closely resemble normal­ appearing white matter.
Pseudoatrophy. As discussed above, studies of the cor­
relation between inflammatory disease activity (new T2 
and/or gadolinium enhancing lesions) and brain volume 
have shown that inflammation can cause a transient 
increase in brain volume. This increase can dramat­
ically resolve following treatment with steroids132 or 
other disease­ modifying drugs, and the resultant reduc­
tion in brain volume can be erroneously interpreted as 
atrophy133.
Evidence review: volumetry tools
Several free­ to­use online libraries of software for neuro­
imaging analyses include fully automated pipelines for 
quantification of brain volume (Table 2). On the basis of 
the current literature that relates to this software, these 
software tools can be classified into two broad catego­
ries. The first are ‘segmentation­ based’ tools, which use 
a priori localization­ related and intensity information 
to classify the brain voxels of each MRI without using 
information from brain MRI images taken at different 
time points. These tools do not enable direct evaluation 
of volumetric changes over time. This type of software is 
mostly used in cross­ sectional analyses. The second are 
the ‘registration­ based’ tools, which enable comparison 
of brain MRI images from the same individual acquired 
over time and are based on an initial registration step; 
this type of software is used in longitudinal analyses134.
Most segmentation­ based software packages provide 
measures of total brain volume, grey matter volume and 
white matter volume based on the partial volume estimation 
(PVE) of each tissue in each voxel. The initial step is 
assignment of the PVE to a given brain voxel on the 
basis of its intensity and the intensities of the surrounding 
Brain parenchymal fraction
The percentage of the 
intracranial volume that is 
occupied by brain parenchyma, 
calculated as the total 
intracranial volume minus the 
volume of cerebrospinal fluid 
divided by the total intracranial 
volume.
Partial volume estimation
(PVe). The proportions of  
white matter, grey matter and 
cerebrospinal fluid present  
in each voxel of an Mri image.
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voxels113. To improve the segmentation, the a priori spa­
tial information for each voxel can be included, thereby 
increasing the probability that each voxel belongs to spe­
cific tissue type on the basis of its location135, although 
the accuracy of this step strongly depends on the ana­
tomical similarity between the MRI image and the 
a priori tissue maps used. To avoid problems due to an 
anatomical mismatch with the atlas, only MRI images 
with high anatomical similarity should be used to pro­
vide the voxel location information136. Use of different 
anatomical maps, such as probability maps of tissues or 
structure labelling maps, can also offer improvements137. 
Other approaches that do not depend on the PVE can 
provide a measure of cortical thickness by calculating 
the distances between pairs of voxels at the grey matter–
white matter and grey matter–CSF interfaces perpendic­
ular to the grey matter–white matter surface interface. 
These methods tend to be more susceptible than some of 
the previously mentioned methods to the low­ intensity 
contrast between tissues because they heavily rely on the 
gradient intensities between tissue interfaces138,139.
Registration­ based software packages provide mea­
sures of total brain volume, grey matter volume and white 
matter volume changes by comparison of serially acquired 
MRI images from the same individual. A common prelim­
inary step in most of these procedures is registration of all 
MRI images from the same subject on the same virtual 
space. The first such software packages that were used 
in longitudinal analyses113,140 involved registration of two 
MRI images of the same individual and measurement of 
whole brain volume change by analysing the shift of the 
parenchyma–CSF border over time. Newer approaches 
apply different methods to enable assessment of grey 
matter and white matter volume changes. In one, for each 




SIENAX Yes Global and regional brain volumes for cross- 
sectional comparisons
Segmentations are affected by the presence of  
brain lesions
SPM/VBM Yesb Global and regional brain volumes, pixel- 
to-pixel statistical comparisons between two 
groups or time points
Segmentations are affected by the presence of  
brain lesions
GIF Yes Regional brain volumes for cross- sectional 
comparisons
Time consuming; data analysed remotely
Atropos Yes Regional brain volumes for cross- sectional 
and longitudinal comparisons
Limited information about the method as it has not 
been used extensively
FreeSurfer Yes Cortical thickness, global and regional grey 
matter and white matter volumes
Time- consuming; requires manual correction of the 
segmented surfaces; segmentations are affected by 
the presence of lesions
CIVET No Cortical thickness Software not freely available
SIENA Yes Percentage brain volume change between 
two time points
Only provides global measures that include grey 
matter and white matter
SIENA- XL No Grey matter and white matter volumes for 
longitudinal comparisons
Software not freely available
SIENAX- MTP No Grey matter and white matter volumes for 
longitudinal comparisons
Software not freely available
BBSI Yes Percentage brain volume change between 
two time points
Only provides global measures that include grey 
matter and white matter
CL ADA No Cortical thickness Software not freely available
NeuroQuant (FDA clearance 
and CE mark received)
No Global and regional grey matter volumes Validation of results is only external; segmentations 
affected by the presence of brain lesions; only images 
from the scanner can be analysed (that is, filled 
images cannot be used)
Icometrix (FDA clearance and 
CE mark received)
No Global and regional grey matter volumes Whole verification of the results is not direct; data 
analysed remotely
Biometrica (CE mark received) No Global and regional grey matter volumes Whole verification of the results is not direct
Quantib (FDA clearance and 
CE mark received)
No Global and regional grey matter volumes Whole verification of the results is not direct
Cordial Yes Spinal cord volume Limited information about the method as it has not 
been used extensively
Spinal Cord Toolbox Yes Spinal cord area, volume and length Regions of interest should be edited and manually 
corrected
JIM No Spinal cord area, volume and length Needs several reference marks for accurate estimates
BBSI, Brain boundary shift integral; CE, Conformité Européenne; CL ADA , cortical longitudinal atrophy detection; GIF, Geodesical information flows; JIM, Jacobian 
integration method; SIENA , Structural Image Evaluation, using Normalization, of Atrophy; SPM, statistical parametric mapping; VBM, voxel- based morphometry. 
aNot exhaustive, only major limitations are included. bSPM itself is free but a MATL AB licence is needed.
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voxel, the intensity information from neighbouring voxels 
at each time point is used141. In another, a new intensity 
harmonization scheme is applied to all MRI images from 
one individual, with the aim of assigning similar inten­
sity to voxels with similar content of PVE142. Another 
approach, known as the Jacobian integration method143,144, 
is based on local assessment of relative volumetric differ­
ences between two MRI images of the same individual, 
one of which is usually the baseline image; the net sum 
of all local volumetric changes provides an estimate of 
total volume changes over time. Finally, cortical thickness 
changes can be detected by the use of a within­subject tem­
plate (an MRI image created by merging all MRI images 
from one individual) to improve cortical thickness esti­
mation at each time point, or by fitting a subject­specific 
cortical deformable model at each time point145,146.
Assessment of spinal cord atrophy is more difficult 
than brain segmentation owing to particular anatomical 
(higher mobility and smaller dimensions than the brain) 
and imaging (lower tissue contrast) features of the spinal 
cord. Semiautomated (Cordial)147 and automated (Spinal 
Cord Toolbox)148 tools have now been developed, based 
on deformable models. These promising new software 
tools still need to be extensively validated on independent 
datasets before they can even be considered for use in 
clinical practice.
Academic software packages have important advan­
tages over commercial software packages, such as the 
fact that they have been validated in many studies under 
a plethora of different MRI conditions over the past dec­
ade. However, they have the severe limitation of being 
highly technically demanding and their use is therefore 
limited to centres that are specialized in MRI processing. 
In addition, clinical application of software to support 
diagnosis or care is only permitted with products that 
have received the “Conformité Européenne” (CE) mark 
in Europe or FDA clearance in the USA. For this reason, 
translation of imaging analysis software tools to clini­
cal practice is challenging and almost unfeasible for 
academic neuroimaging laboratories.
In the past 10 years, several companies have proposed 
centralized MRI reading services, often using their in­ 
house software for quantification of atrophy (Table 2). 
Four software packages have been approved for use in 
Europe and three of these have also received FDA clear­
ance in the USA. The IcoBrain MS (Icometrix, previ­
ously MSmetrix)149 quantifies cross­ sectional volumes 
with software based on Nifty Seg and quantifies longitu­
dinal changes in grey matter and white matter with soft­
ware that implements Jacobian integration. NeuroQuant 
(CorTechs Labs)150 provides both cross­ sectional and 
longitudinal quantification of atrophy151, building on 
approaches already developed by previous methods138. 
Biometrica MS (Jung Diagnostics) builds on develop­
ments of Statistical Parametric Mapping, a software 
library for neuroimaging analysis, for atrophy measure­
ment and of Lesion Segmentation Tool software for auto­
matic lesion segmentation152,153. Quantib Brain (Quantib) 
is a platform that is integrated into the General Electric 
MRI scanner and can assess cross­ sectional brain vol­
umes and longitudinal changes in volume. IcoBrain 
MS and Biometrica MS are offered as remote analysis 
services, Quantib Brain can be run locally or on a vendor 
console (General Electric), and NeuroQuant can be a 
remote analysis service or local installation. All packages 
have the CE mark and, with the exception of Biometrica, 
FDA clearance. These certifications guarantee standard­
ization of procedures and results, meaning the software 
can be used as medical devices.
Importantly, the companies must provide the magni­
tude of the error in their results, and health care profes­
sionals should use this information to validate or discard 
findings of analyses. All four commercial software pack­
ages have been evaluated scientifically to some extent but 
not completely. To our knowledge, only MSmetrix has 
been validated by an independent group in the context of 
MS154. Furthermore, the real­ world clinical value of these 
software packages has not yet been assessed, and the pro­
cedures are not widely reimbursed (with a few exceptions, 
such as in the USA). Although promising, these analyt­
ical approaches should therefore be more extensively 
validated by expert groups in the field of MRI preprocess­
ing, especially in the context of MS134, before they can be 
considered for use in the routine clinical setting.
Statements and recommendations
1. We recommend appropriate management of several 
scanner­ related factors (including, but not limited to, 
variation in acquisition protocols, different scanner 
systems and upgrades, movement artefacts and gra­
dient distortions) to ensure reliability of brain volume 
estimates, particularly at an individual patient level.
2. We recommend appropriate management of physio­
logical and MS­ related factors (including, but not 
limited to, age, sex, hydration status, time of day, 
steroid use and MS­ related parenchymal alterations).
3. Brain volume measures are software­ dependent so 
the use of software that has been approved as a med­
ical device and independently evaluated in MS is a 
prerequisite; we recommend further research to vali­
date existing software tools in MS and assess their 
clinical value.
Conclusions and future directions
Based on the evidence reviewed, the idea that brain vol­
ume changes and, to a lesser extent, spinal cord atrophy 
are helpful predictors of the evolution of MS before ini­
tiation of therapy is undisputed, so these measures could 
be valid treatment­ decision tools. The evidence reviewed 
also supports the idea that brain volume measures have 
value in monitoring the effects of MS drugs as part of 
the no evidence of disease activity outcome measure or 
minimal evidence of disease activity outcome measure. 
However, several potential sources of substantial error 
remain, including, but not limited to, differential effects of 
drugs on brain volume measures, confounding physio­
logical and technical factors and the performance and 
value of volumetric tools. To make implementation of 
volume measurements in clinical practice feasible, these 
potential sources of error need to be accounted for and 
appropriately managed, and further research is needed to 
ensure the accuracy and reliability of the measurements.
Published online 24 February 2020
Deformable model
a mathematical construct 
capable of representing a 
broad range of shapes that can 
be used in Mri image 
registration or segmentation.
Nifty Seg
an open- source image analysis 
tool developed at University 
College london to perform 
segmentations of Mri images.
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